Get the Stockscreener App
24.15
1.90%
0.45
After Hours:
24.50
0.35
+1.45%
Immunovant Inc stock is traded at $24.15, with a volume of 523.95K.
It is up +1.90% in the last 24 hours and up +9.87% over the past month.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
See More
Previous Close:
$23.70
Open:
$24
24h Volume:
523.95K
Relative Volume:
0.30
Market Cap:
$4.23B
Revenue:
-
Net Income/Loss:
$-382.71M
P/E Ratio:
-9.2176
EPS:
-2.62
Net Cash Flow:
$-325.64M
1W Performance:
+6.91%
1M Performance:
+9.87%
6M Performance:
+71.28%
1Y Performance:
-15.94%
1-Day Range:
$23.80
$24.42
1-Week Range:
$22.43
$24.42
52-Week Range:
$12.72
$29.49
Immunovant Inc Stock (IMVT) Company Profile
Name
Immunovant Inc
Sector
Industry
Phone
917-580-3099
Address
320 WEST 37TH STREET, NEW YORK, NY
Compare IMVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
24.15 | 4.15B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-25 | Initiated | Truist | Hold |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Mar-03-25 | Initiated | Jefferies | Hold |
| Jan-03-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-09-24 | Reiterated | Oppenheimer | Outperform |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Mar-13-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | JP Morgan | Overweight |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-13-23 | Upgrade | UBS | Neutral → Buy |
| Sep-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-23 | Initiated | BofA Securities | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-31-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Feb-15-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-13-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-26-22 | Downgrade | UBS | Buy → Neutral |
| Dec-08-21 | Initiated | Wells Fargo | Equal Weight |
| Aug-03-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Aug-02-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jun-01-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-21 | Downgrade | Stifel | Buy → Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-12-20 | Initiated | Guggenheim | Buy |
| Oct-08-20 | Initiated | Stifel | Buy |
| Oct-02-20 | Initiated | Credit Suisse | Outperform |
| Aug-26-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Jul-29-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | SVB Leerink | Outperform |
View All
Immunovant Inc Stock (IMVT) Latest News
Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings - Insider Monkey
(IMVT) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
12 Best Short Squeeze Stocks to Buy Right Now - Insider Monkey
Officer Geffner Files To Sell 50,000 Of Immunovant Inc [IMVT] - TradingView
Immunovant (IMVT): Assessing Valuation Following R&D Leadership Restructuring and CMO Departure - Sahm
JPMorgan Lowers PT on Immunovant (IMVT) to $33 From $37 - MSN
Have Insiders Sold Immunovant Shares Recently? - simplywall.st
Immunovant Restructures R&D Leadership with CMO Departure - The Globe and Mail
Immunovant COO Gloria sells $298k in shares By Investing.com - Investing.com Nigeria
Immunovant COO Gloria sells $298k in shares - Investing.com
Immunovant Insider Sold Shares Worth $298,237, According to a Recent SEC Filing - MarketScreener
Immunovant COO Gloria Melanie Sells Shares to Cover Tax Obligations - TradingView
[Form 4] Immunovant, Inc. Insider Trading Activity - Stock Titan
[8-K] Immunovant, Inc. Reports Material Event | IMVT SEC FilingForm 8-K - Stock Titan
Immunovant, Inc. Announces Cessation of Michael Geffner, M.D., M.B.A. as Chief Medical Officer, Effective November 21, 2025 - MarketScreener
How analysts rate Immunovant Inc. stock todayInsider Selling & Technical Entry and Exit Tips - newser.com
Will Immunovant Inc. stock outperform value stocksTrade Exit Summary & Weekly Breakout Watchlists - newser.com
Is Immunovant Inc. stock affected by interest rate hikesJuly 2025 Gainers & Stepwise Trade Signal Implementation - newser.com
Can swing trading help recover from Immunovant Inc. losses2025 Pullback Review & Accurate Intraday Trading Signals - newser.com
How Immunovant Inc. stock performs after earningsJuly 2025 Spike Watch & Community Consensus Trade Signals - newser.com
Responsive Playbooks and the IMVT Inflection - news.stocktradersdaily.com
Is Immunovant Inc. meeting your algorithmic filter criteriaPortfolio Value Summary & Safe Capital Growth Stock Tips - newser.com
Is Immunovant Inc. stock oversold or undervalued2025 Price Momentum & Weekly High Potential Alerts - newser.com
Key resistance and support levels for Immunovant Inc.Global Markets & Risk Adjusted Swing Trade Ideas - newser.com
Will Immunovant Inc. stock go up soonTrade Performance Summary & Free Low Drawdown Momentum Trade Ideas - newser.com
Sentiment analysis tools applied to Immunovant Inc.Weekly Stock Report & Low Risk High Win Rate Stock Picks - newser.com
Why Immunovant Inc. stock is popular among millennials2025 Technical Overview & Community Consensus Picks - newser.com
Why Immunovant Inc. stock is recommended by analystsWeekly Trade Analysis & Consistent Income Trade Ideas - newser.com
How institutional ownership impacts Immunovant Inc. stockMarket Activity Summary & Daily Profit Maximizing Trade Tips - newser.com
Immunovant, Inc. (NASDAQ:IMVT) Q2 2025 Earnings Call Transcript - Insider Monkey
Immunovant Inc Stock Analysis and ForecastStock Buyback Updates & Explosive Capital Growth Plans - earlytimes.in
Immunovant’s Earnings Call Highlights Clinical Success and Financial Strength - MSN
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus - MSN
Immunovant stock rating reiterated by Oppenheimer, cites progress in autoimmune portfolio - Investing.com South Africa
Immunovant Bets Big On Autoimmune Drug Pipeline Progress - Finimize
Immunovant, Inc. (NASDAQ:IMVT) Q2 2026 Earnings Call Transcript - Insider Monkey
Immunovant Inc Stock (IMVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):